Literature DB >> 21740059

Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency.

Ajay N Singh1, Wei Liu, Guiyang Hao, Amit Kumar, Anjali Gupta, Orhan K Öz, Jer-Tsong Hsieh, Xiankai Sun.   

Abstract

The role of the multivalent effect has been well recognized in the design of molecular imaging probes toward the desired imaging signal amplification. Recently, we reported a bifunctional chelator (BFC) scaffold design, which provides a simple and versatile approach to impart multivalency to radiometal based nuclear imaging probes. In this work, we report a series of BFC scaffolds ((t)Bu(3)-1-COOH, (t)Bu(3)-2-(COOH)(2), and (t)Bu(3)-3-(COOH)(3)) constructed on the framework of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) for (68)Ga-based PET probe design and signal amplification via the multivalent effect. For proof of principle, a known integrin α(v)β(3) specific ligand (c(RGDyK)) was used to build the corresponding NOTA conjugates (H(3)1, H(3)2, and H(3)3), which present 1-3 copies of c(RGDyK) peptide, respectively, in a systematic manner. Using the integrin α(v)β(3) binding affinities (IC(50) values), enhanced specific binding was observed for multivalent conjugates (H(3)2: 43.9 ± 16.1 nM; H(3)3: 14.7 ± 5.0 nM) as compared to their monovalent counterpart (H(3)1: 171 ± 60 nM) and the intact c(RGDyK) peptide (204 ± 76 nM). The obtained conjugates were efficiently labeled with (68)Ga(3+) within 30 min at room temperature in high radiochemical yields (>95%). The in vivo evaluation of the labeled conjugates, (68)Ga-1, (68)Ga-2, and (68)Ga-3, was performed using male severe combined immunodeficiency (SCID) mice bearing integrin α(v)β(3) positive PC-3 tumor xenografts (n = 3). All (68)Ga-labeled conjugates showed high in vivo stability with no detectable metabolites found by radio-HPLC within 2 h postinjection (p.i.). The PET signal amplification in PC-3 tumor by the multivalent effect was clearly displayed by the tumor uptake of the (68)Ga-labeled conjugates ((68)Ga-3: 2.55 ± 0.50%ID/g; (68)Ga-2: 1.90 ± 0.10%ID/g; (68)Ga-1: 1.66 ± 0.15%ID/g) at 2 h p.i. In summary, we have designed and synthesized a series of NOTA-based BFC scaffolds with signal amplification properties, which may find potential applications as diagnostic gallium radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740059      PMCID: PMC3170926          DOI: 10.1021/bc200227d

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  55 in total

1.  Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.

Authors:  Xianzhong Zhang; Zhengming Xiong; Yun Wu; Weibo Cai; Jeffery R Tseng; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

2.  Multivalent effects of RGD peptides obtained by nanoparticle display.

Authors:  Xavier Montet; Martin Funovics; Karin Montet-Abou; Ralph Weissleder; Lee Josephson
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

Review 3.  Integrated PET/CT: current applications and future directions.

Authors:  Gustav K von Schulthess; Hans C Steinert; Thomas F Hany
Journal:  Radiology       Date:  2006-02       Impact factor: 11.105

4.  The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform.

Authors:  Seungpyo Hong; Pascale R Leroueil; István J Majoros; Bradford G Orr; James R Baker; Mark M Banaszak Holl
Journal:  Chem Biol       Date:  2007-01

Review 5.  68Ga-PET radiopharmacy: A generator-based alternative to 18F-radiopharmacy.

Authors:  H R Maecke; J P André
Journal:  Ernst Schering Res Found Workshop       Date:  2007

6.  Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.

Authors:  Yunpeng Ye; Sharon Bloch; Baogang Xu; Samuel Achilefu
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

7.  Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.

Authors:  Ingrid Dijkgraaf; John A W Kruijtzer; Shuang Liu; Annemieke C Soede; Wim J G Oyen; Frans H M Corstens; Rob M J Liskamp; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-15       Impact factor: 9.236

Review 8.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Authors:  Shuang Liu
Journal:  Mol Pharm       Date:  2006 Sep-Oct       Impact factor: 4.939

9.  (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.

Authors:  Zi-Bo Li; Weibo Cai; Qizhen Cao; Kai Chen; Zhanhong Wu; Lina He; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

10.  Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.

Authors:  Ingrid Dijkgraaf; Anneloes Y Rijnders; Annemieke Soede; Annemarie C Dechesne; G Wilma van Esse; Arwin J Brouwer; Frans H M Corstens; Otto C Boerman; Dirk T S Rijkers; Rob M J Liskamp
Journal:  Org Biomol Chem       Date:  2007-01-29       Impact factor: 3.876

View more
  10 in total

1.  Evaluation of novel 99mTc(I)-labeled homobivalent α-melanocyte-stimulating hormone analogs for melanocortin-1 receptor targeting.

Authors:  Maurício Morais; Paula D Raposinho; Maria Cristina Oliveira; João D G Correia; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2012-04       Impact factor: 3.358

2.  Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.

Authors:  Irina Velikyan; Örjan Lindhe
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

3.  Universal Molecular Scaffold for Facile Construction of Multivalent and Multimodal Imaging Probes.

Authors:  Yongkang Gai; Guangya Xiang; Xiang Ma; Wenqi Hui; Qin Ouyang; Lingyi Sun; Jiule Ding; Jing Sheng; Dexing Zeng
Journal:  Bioconjug Chem       Date:  2016-02-24       Impact factor: 4.774

4.  Trigonal scaffolds for multivalent targeting of melanocortin receptors.

Authors:  N G R Dayan Elshan; Thanuja Jayasundera; Bobbi L Anglin; Craig S Weber; Ronald M Lynch; Eugene A Mash
Journal:  Org Biomol Chem       Date:  2015-02-14       Impact factor: 3.876

5.  Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.

Authors:  Mai Lin; Michael J Welch; Suzanne E Lapi
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

6.  A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.

Authors:  Guiyang Hao; Amit Kumar; Timothy Dobin; Orhan K Oz; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-06-28       Impact factor: 4.939

7.  Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.

Authors:  David E Gerber; Guiyang Hao; Linda Watkins; Jason H Stafford; Jon Anderson; Blair Holbein; Orhan K Öz; Dana Mathews; Philip E Thorpe; Gedaa Hassan; Amit Kumar; Rolf A Brekken; Xiankai Sun
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

Review 8.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

9.  Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect.

Authors:  Ajay N Singh; Michael J McGuire; Shunzi Li; Guiyang Hao; Amit Kumar; Xiankai Sun; Kathlynn C Brown
Journal:  Theranostics       Date:  2014-05-15       Impact factor: 11.556

10.  Molecular dynamics simulation of Fe-NO2 At-alpha mangostin as radiopharmaceutical model for detection of fatty acid synthase in cancer.

Authors:  N Elly Rosilawati; Muhamad Yusuf; Achmad Hussein S Kartamihardja; Shaharum Samsuddin; Muchtaridi Muchtaridi
Journal:  J Adv Pharm Technol Res       Date:  2021-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.